HER2-NEGATIVE BREAST CANCER

This study is testing whether giving hormone therapy before surgery helps women with a specific type of breast cancer have better surgical outcomes. Researchers want to see if this approach reduces the chance that cancer cells are left at the edges of removed tissue, which often …

This study is testing if the weight loss medication tirzepatide can help people with early-stage, hormone-positive breast cancer lose weight and potentially improve their long-term outcomes. It will involve 40 participants who have finished their main cancer treatment but are ove…

This study is testing whether adding the drug ribociclib to standard hormone therapy can better prevent breast cancer from returning in patients who have already had a local recurrence surgically removed. The trial will enroll 200 adults with hormone-sensitive, HER2-negative brea…

This study is testing whether different antibody-drug conjugate (ADC) medications can help control advanced breast cancer in patients whose cancer has progressed despite previous ADC treatment. The trial will enroll 160 adults with metastatic breast cancer who have already receiv…

This study is testing whether giving radiation treatment a second time is safe for women whose breast cancer has returned in the same breast. Researchers want to understand both the benefits and risks of this approach for patients who have already had radiation therapy. The study…

This study is comparing two ways to give radiation during breast-conserving surgery for early breast cancer. It will follow 620 women aged 55+ to see which method better prevents cancer from returning locally and causes fewer complications. One group gets a single dose of radiati…

This study is testing whether combining three existing cancer drugs works better to control advanced breast cancer that has spread. It's for people whose cancer is fueled by hormones and has either just been diagnosed as advanced or returned after more than a year. The main goal …

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This study is testing a new drug combination for premenopausal women with a common type of breast cancer (ER+/HER2-) before they have surgery. The goal is to see if taking the drug (Z)-endoxifen with a monthly injection (goserelin) can slow or stop tumor growth, potentially shrin…

This study is testing whether switching between two newer cancer drugs can help control advanced breast cancer that has spread and stopped responding to a similar prior treatment. It will involve about 357 people with HER2-negative metastatic breast cancer. The main goal is to se…

This study is testing whether adding chemotherapy delivered directly into the spinal fluid (through a small implanted device called an Ommaya reservoir) works better than standard chemotherapy alone for people with HER2-negative breast cancer that has spread to the membranes surr…

This early-stage study is testing a new experimental drug called BGB-43395, both alone and in combination with other cancer medications, for people with advanced hormone-positive breast cancer and other solid tumors. The main goals are to find safe dosage levels and see if the dr…

This early-stage study aims to find safe and effective doses for a new breast cancer drug, palazestrant, when combined with four different existing cancer drugs. It will enroll about 190 adults with advanced or metastatic ER-positive, HER2-negative breast cancer who have had limi…

This is the first study in people to test a new drug called RLY-2608, which is designed to target a specific genetic mutation (PIK3CA) found in many advanced solid tumors and breast cancers. The main goals are to find the safest and most effective dose, check for side effects, an…

This study is testing whether adding a drug called retinoic acid to standard immunotherapy can help control advanced HER2-negative breast cancer that has started growing again during previous immunotherapy. It aims to see if this combination can shrink tumors or stop their growth…

This early-stage study aims to find the safest and most effective dose of the drug abemaciclib when given at the same time as targeted radiation therapy. It is for people with advanced, hormone-sensitive breast cancer that has spread to the bones. The goal is to see if this combi…

This study is testing if a new device called TheraBionic P1 can help shrink tumors in people with early-stage breast cancer before they have surgery. The device uses specific radio waves aimed at cancer cells. Researchers will enroll 24 participants to see if adding this device t…

This study is testing whether adding the drug everolimus to a newer hormone therapy (elacestrant) works better for controlling advanced breast cancer than the hormone therapy alone. It is for people whose cancer has a specific mutation (ESR1) and has continued to grow despite sta…

This is an early safety study testing a new two-part treatment for advanced breast cancer that has spread. It combines a personalized vaccine made from a patient's own immune cells with a hormone-blocking pill. The goal is to see if this combination is safe and feasible for patie…

This early-stage study is testing whether new drug combinations are safe for people with advanced hormone-positive breast cancer that has spread. Researchers will give 120 participants either two or three drugs together to see how well they're tolerated and if they help shrink tu…

This early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer. The goal is to see if a combination of high-dose chemotherapy drugs, vitamins, and the patient's own stem cells is safe and can overcome the cancer's resistance to treatment.…

This study is testing whether combining precise brain radiation with two cancer drugs (anlotinib and a tubulin inhibitor) can better control breast cancer that has spread to the brain. It is for women with HER2-negative breast cancer who have brain metastases. The main goal is to…

This study is testing whether the drug sacituzumab govitecan, alone or combined with pembrolizumab, can shrink tumors before surgery in people with localized triple-negative breast cancer. About 260 participants will receive the study treatment for up to 12 weeks, followed by sta…

This early-stage study is testing a new type of personalized vaccine, made from a patient's own immune cells, given directly into the tumor along with standard chemotherapy. It aims to see if this combination is safe and can help shrink tumors in people with aggressive forms of b…

This study is testing a new three-drug combination for people with a rare and aggressive type of breast cancer called metaplastic breast cancer (MpBC), which has stopped responding to standard treatments. The goal is to see if adding two new drugs (alpelisib and L-NMMA) to a stan…

This study is testing a personalized approach to reduce chemotherapy for women with a common type of early-stage breast cancer. It uses a simple blood test to see if a targeted pill (dalpiciclib) combined with hormone therapy works as well as standard chemo before surgery. The go…

This study is testing if adding the drug capivasertib to standard hormone therapy can help people with a specific type of advanced breast cancer stay on their treatment longer and maintain their quality of life. It is for adults whose cancer has continued to grow despite prior ho…

This trial aims to find the best drug combinations for different types of breast cancer before surgery. It tests new drugs alongside standard chemotherapy in 5,000 women with early-stage or locally advanced breast cancer. The study uses tumor analysis and MRI scans to match treat…

This study is testing a new decision-making tool for women aged 70 and older who have a common, low-risk type of early breast cancer. The goal is to see if giving patients a detailed guide and training their surgeons in shared decision-making leads to fewer aggressive treatments …

This study is for people with a specific type of advanced breast cancer that has continued to grow despite standard hormone therapy. Researchers want to see if starting one drug a month before adding a second drug is more effective than starting both together. The goal is to find…

This global Phase 3 trial is testing which of two drug combinations works better to control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after standard hormone therapy. It will enroll about 540 adults whose cancer has returned or sp…

This is an early-stage study to check the safety and initial activity of an experimental drug called DR-0202. It is for adults with advanced cancers that have spread, returned, or stopped responding to at least two prior treatments. The main goal is to find a safe dose and see ho…

This study is evaluating a genomic test called EndoPredict that helps predict the 10-year risk of breast cancer returning. It aims to see if the test can reliably identify patients with a low risk of recurrence, so they can safely avoid chemotherapy and receive hormone therapy al…

This study aims to understand how consistently patients take their breast cancer medications. Researchers will compare two groups: those taking a standard hormone therapy pill versus those taking that pill plus an additional drug called abemaciclib. They will track 319 patients f…

This study is testing a blood test called DiviTum®TKa to see if it can predict early whether standard hormone-based treatments for advanced breast cancer will stop working. Researchers will measure a specific marker in the blood of 100 patients with hormone-positive, HER2-negativ…

This study is testing whether a new optical scanning device called NearWave can monitor how breast cancer responds to chemotherapy before surgery. Researchers will use the device on 15 patients receiving chemotherapy to see if it collects good enough data to predict treatment suc…

This study aims to collect real-world information about how well FDA-approved antibody-drug conjugate (ADC) treatments work for people with advanced HER2-negative breast cancer. Researchers will follow 100 patients receiving these treatments as part of their regular care to under…

This study is testing whether a special imaging scan, originally developed for prostate cancer, can detect a specific marker (PSMA) in certain types of advanced breast cancer. Researchers want to see if this marker can help predict which patients might not respond well to a commo…